Evaluation of the efficacy of the Nm5CV vaccine during the response campaign in Niger

Meningococcal meningitis remains a major public health concern across the African meningitis belt despite the successful elimination of serogroup A epidemics following the introduction of MenAfriVac. However, recurrent outbreaks due to serogroups C, W, and X continue to occur. Men5CV, a pentavalent conjugate vaccine targeting serogroups A, C, W, Y, and X, was prequalified by WHO in 2023 and introduced in Niger during reactive vaccination campaigns in 2024. This presentation sets out the results of a matched case-control study in six health districts in Niger (Niamey I-V and Magaria) to assess the effectiveness of Men5CV against meningococcal meningitis.